Jazz Pharmaceuticals PLC - JAZZ Enterprise Value-to-Sales Ratio

Public company logo of Jazz Pharmaceuticals PLC (JAZZ)

Jazz Pharmaceuticals minimizes industry threats by combining sleep disorder therapies with the development of oncology and rare diseases. The EV/Sales multiple confirms the resilience of this strategy, with 3807.89 serving as the current level of the metric. Profitability is based on patent protection and Xanidatamab margins, while a powerful cash flow is driven by sales of Rylaze and sodium oxybate.

Jazz Pharmaceuticals PLC (JAZZ): Enterprise Value-to-Revenue Ratio from 11/23/2025 to 11/20/2026

Financial and market metric breakdowns for Jazz Pharmaceuticals plc (JAZZ)

Fundamental valuation:Jazz Pharmaceuticals plc
Mass-produced product of jazzpharma.com

This indicator compares the total enterprise value, adjusted for net debt, against the volume of generated revenue, allowing for an assessment of the market value of one dollar of sales regardless of the financing structure. Given the monopoly position of Jazz Pharmaceuticals (JAZZ) in the narcolepsy therapy segment and the stringent regulatory barriers for competitors, the current EV/Sales value reflects a premium for high cash flow stability and the protected nature of the business model.